Intra-Cellular Therapies (ITCI) Announces Proposed $500M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities
April 17, 2024 5:13 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More
